Introduction

During the last 3 decades, liver transplantation (LT) has been the standard treatment for patients affected by liver failure. Nowadays, the 5-year survival rates after LT exceed 70%, with lower comorbidity and mortality compared to the past. Judging from data in the European Liver Transplant Registry (ELTR) (1), a plateau in LTs seems to have been reached in the recent years, with about 7,300 LTs being performed in all of Europe annually. In contrast, data from between 1988 and 2018 from the United Network for Organ Sharing (UNOS) Liver Transplant Registry indicate that liver transplants almost quintupled from 1,713 to 8,250, continuing to slightly increase in the last few years (2).

In the ELTR area (1), the most frequent indication for LT was liver cirrhosis (50%), with 22% of cases being related to viral infection (with a prevalence of hepatitis C virus (HCV) and cirrhosis) and 19% being related to alcohol abuse. Primary liver tumors, predominantly hepatocellular carcinoma, represent 17% of LT indications, followed by cholestatic liver disease [10%, including primary biliary cirrhosis and primary sclerosing cholangitis (PSC)], and...
acute hepatic failure. Indications for LT are under 1% for some diseases like metabolic disorder (familial amyloidotic polyneuropathy, Wilson disease, alpha-1-antitrypsin deficiency), vascular disorders, Budd-Chiari syndrome (BCS), benign liver tumor, and secondary liver tumors (mainly neuroendocrine). Recently, unresectable colorectal liver metastases (CRLM) have garnered interest since the publication of the SECA trial by the University of Oslo (3).

From the last Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) 2017 Annual Data Report (4), 8082 liver transplants were performed in the United States. In the UNOS area, more than 30% of patients underwent LT for non-HCV and non-alcoholic related cirrhosis; nonalcoholic steatohepatitis (NASH) is a rapidly growing etiology of end-stage liver disease in the USA (5). Alcoholic liver disease (23% of LT), followed by primary liver tumors (16%), especially hepatocellular carcinoma, are also growing LT indications. HCV-related liver disease has declined as indications in the last years, accounting for 12% of indications for LT.

Other indications are cholestatic liver disease (11%), including primary biliary cholangitis and PSC; followed by idiopathic/autoimmune liver disease; acute liver failure (7%); and hepatitis B virus (6%). Meanwhile, the more rare indications are metabolic liver diseases, benign liver tumors, and secondary liver tumors.

Both in the ELTR and UNOS areas, rare indications for LT include non-hepatocellular malignancy, vascular disorders, and metabolic and congenital liver disorders. Most of these diseases are not associated with liver failure (hepatic synthetic dysfunction or portal hypertension), but LT represents an effective therapy providing a significant benefit in overall survival and quality of life for these patients.

Rare indications for LT often overlap with rare diseases. Exceptions to this rule (i.e., rare LT indications for non-rare diseases) cover some diseases in which LT is a rising indication: benign primary liver tumor, colon rectal liver metastasis, neuroendocrine liver metastasis, and CCA. These primary and secondary tumors have a medium-to-high incidence in the population, but indication to LT is still rare and undergoing scientific validation. In this article, we will discuss the rare adult diseases with indication for LT and the non-rare diseases with rare indication for LT.

### Classification

A disease is defined as rare when the incidence is below 1 per 10,000. We here propose a classification based on the nature of the disease: non-neoplastic or neoplastic disease.

Furthermore, Tables 1,2,3, based on the Orphanet data propose a classification of the diseases according to the liver injury/alteration that leads to a potential indication for LT. In particular, some rare diseases can lead to: (I) hepatocellular necrosis; (II) biliary tree abnormality, leading to cholestasis; (III) hepatomegaly often resulting from metabolic/vascular dysfunction; (IV) other diseases with possible LT indication.

We will further focus on some disorders for which the literature provides a more definitive evidence base.

### Non-neoplastic diseases with possible indication for LT

**Budd-Chiari**

BCS consists of hepatic venous outflow tract obstruction due to primary causes (thrombosis or phlebitis) or secondary causes (external compression or invasion of the hepatic veins and the vena cava).

According to the clinical manifestations, BCS can be categorized as (6,7): (I) acute liver failure, where jaundice, hepatic encephalopathy, elevation of transaminases, and prothrombin time and international normalized ratio (PT/INR) ratio worsen within a day; (II) acute, where the previous manifestations develops in weeks; (III) subacute, with minor signs presenting in months (8); (IV) chronic, associated with end stage liver disease.

### Table 1 Diseases leading to hepatocellular necrosis

<table>
<thead>
<tr>
<th>Disease</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute liver failure</td>
<td>1–5×10,000</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>1–5×10,000</td>
</tr>
<tr>
<td>Autosomal systemic lupus erythematosus</td>
<td>1×1,000,000</td>
</tr>
<tr>
<td>Classic galactosemia</td>
<td>1×40000</td>
</tr>
<tr>
<td>Hereditary fructose intolerance</td>
<td>1–9×100,000</td>
</tr>
<tr>
<td>Macrophage activation syndrome</td>
<td>n.d.</td>
</tr>
<tr>
<td>Neonatal hemochromatosis</td>
<td>1×100,000,000</td>
</tr>
<tr>
<td>Rare HH</td>
<td>n.d.</td>
</tr>
<tr>
<td>Tyrosinemia type 1</td>
<td>1×100,000</td>
</tr>
<tr>
<td>Wilson disease</td>
<td>1–9×100,000</td>
</tr>
</tbody>
</table>

n.d., no data.

© Translational Gastroenterology and Hepatology. All rights reserved.
<table>
<thead>
<tr>
<th>Disease</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alagille syndrome</td>
<td>1×100,000</td>
</tr>
<tr>
<td>Alfa-1 antitrypsin</td>
<td>1×2,500</td>
</tr>
<tr>
<td>Biliary atresia with splenic malformation syndrome</td>
<td>1–9×1,000,000</td>
</tr>
<tr>
<td>Choledochal cyst</td>
<td>n.d.</td>
</tr>
<tr>
<td>Crigler-Najjar syndrome</td>
<td>1–9×10,000</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>1–9×100,000</td>
</tr>
<tr>
<td>Familial intrahepatic cholestasis</td>
<td>n.d.</td>
</tr>
<tr>
<td>Fulminant viral hepatitis</td>
<td>n.d.</td>
</tr>
<tr>
<td>Hepatic fibrosis-renal cyst intellectual disability syndrome (Thompson-Baraitser syndrome)</td>
<td>1×1,000,000</td>
</tr>
<tr>
<td>Idiopathic ductopenia</td>
<td>n.d.</td>
</tr>
<tr>
<td>Isolated biliary atresia</td>
<td>1–9×100,000</td>
</tr>
<tr>
<td>Isolated congenital hepatic fibrosis</td>
<td>n.d.</td>
</tr>
<tr>
<td>Primary biliary cholangitis</td>
<td>1–5×10,000</td>
</tr>
<tr>
<td>Rare tumor of the gallbladder and extrahepatic biliary tract</td>
<td>n.d.</td>
</tr>
<tr>
<td>Sclerosing cholangitis</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

n.d., no data.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beckwith-Wiedemann syndrome</td>
<td>1–5×10,000</td>
</tr>
<tr>
<td>Caroli disease</td>
<td>1×1,000,000</td>
</tr>
<tr>
<td>Congenital anomaly of hepatic vein</td>
<td>n.d.</td>
</tr>
<tr>
<td>Congenital portosystemic shunt</td>
<td>n.d.</td>
</tr>
<tr>
<td>Glycogen storage disease due to glucose-6-phosphatase deficiency</td>
<td>1×100,000</td>
</tr>
<tr>
<td>Glycogen storage disease due to glycogen-branching enzyme deficiency</td>
<td>n.d.</td>
</tr>
<tr>
<td>Hepatic veno-occlusive disease</td>
<td>1–5×10,000</td>
</tr>
<tr>
<td>Isolated PLD</td>
<td>1×1,000,000</td>
</tr>
<tr>
<td>Langerhans cell histiocytosis</td>
<td>1–9×100,000</td>
</tr>
<tr>
<td>BCS</td>
<td>1–9×100,000</td>
</tr>
<tr>
<td>Nodular regenerative hyperplasia of the liver</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

n.d., no data.

An initial evaluation can be made with doppler ultrasonography and computed tomography (CT) scan, but venography is still considered the gold standard for definitive diagnosis. A sulfur-colloid scintigraphy is an alternative option to confirm the diagnosis (6). The treatment is tailored according to the underlying cause: thrombolysis, angioplasty/stenting, and medical treatments of portal hypertension.

LT should be considered when first-line treatments do not succeed or in the case of advanced cirrhosis.
Patients undergoing LT have a chance to survive according to model for end-stage liver disease (MELD) score: the higher the MELD score is, the worse the outcome (9,10). LT for BCS in the pre-MELD era compared to MELD era showed a worse 3-year graft (81% vs. 65%) and patient survival (85% vs. 73%) (11).

Mentha et al.’s study of a cohort of 248 patients transplanted for BCS reported an overall survival (OS) of 71% after 5 years and 68% after 10 years; the highest mortality rate occurred within the first 3 months after LT, especially in the patients with impaired renal function and previous shunt (9). Meanwhile, other studies suggest that patients affected with BCS have higher risk of vascular complications after LT (10).

**Caroli disease**

Caroli disease is a congenital disorder characterized by multifocal, segmental dilatation of large intrahepatic bile ducts (12) and is often associated with renal cystic disease. There are two variants of the disease: Caroli disease (a rare form with bile ductular ectasia) and Caroli syndrome (a more common form, associated with congenital hepatic fibrosis).

Caroli disease and syndrome may be parts of more complex diseases, including nephronophthisis, Meckel-Gruber syndrome, COACH syndrome, Joubert syndrome, Bardet-Biedl syndrome, and oral-facial-digital syndrome.

The pathogenesis of Caroli disease is unclear, but it is usually related to gene mutations in the *PKHD1* gene, which has been localized to the chromosome 6p21.1-p12, and is frequently associated with autosomal recessive polycystic kidney disease (ARPKD).

Clinical manifestations are secondary to bile duct abnormalities and portal hypertension due to portal fibrosis. Diagnosis is generally established through a radiological approach, including ultrasound (US), endoscopic retrograde cholangiopancreatography (ERCP) and/or magnetic resonance imaging (MRI) in order to show bile duct ectasia and irregular, cystic dilation of the large proximal intrahepatic bile ducts. These findings could help to exclude extrahepatic choledochal cysts (type V) (13).

The first line of treatment is medical and prevents complications from cholangitis, portal hypertension (esophageal varices), and rarely, liver failure (13-15). In the case of refractory disease, LT may be the only option. The largest series of 140 patients with Caroli disease or syndrome transplanted between 1987 and 2011 reported an excellent OS (16).

**Hepatic sinusoidal obstruction syndrome (SOS)**

Hepatic SOS, formerly known as hepatic veno-occlusive disease is a rare disease similar to BCS. In SOS, the occlusion-causing hepatic venous outflow obstruction affects the terminal hepatic venules and hepatic sinusoids. Clinical features are similar to BCS, and patients present right upper quadrant pain, jaundice, and ascites. Hepatomegaly is typical. SOS is often secondary to hematopoietic cell transplantation (HCT) or monoclonal antibody treatment (17-20). Female sex and reduced lung diffusing capacity, along with the use of amphotericin, vancomycin, and acyclovir, are risk factors associated with SOS (19).

Diagnosis should be considered in case of patients receiving HCT, and the modified Seattle criteria (19) are a useful tool in diagnosing suspect SOS when 2 or more of the following events are present: bilirubin ≥2 mg/dL, hepatomegaly and upper right quadrant pain, or sudden weight gain due to fluid accumulation.

A large variety of pathological findings can be ascertained through US, CT scan, and MRI, but a liver biopsy is mandatory and also enables a differential diagnosis, particularly with BCS. SOS due to tacrolimus has been reported in lung and pancreatic transplantation, but has never been described in LT recipients (21,22).

Patients with SOS are usually frail patients, with poor performance status due to other therapies such as radiotherapy or chemotherapy. In this scenario, the indication and the timing to LT has to be strict (19). So far, there is no evidence concerning LT safety. Only few case reports describe a good outcome, while several other studies show high risks of post-operative complications and graft versus host disease (22-24).

**Metabolic diseases**

A large variety of metabolic diseases can lead to liver injury and failure, but LT is not always necessary or recommended. The following section describes the most common metabolic diseases that can require LT.

**Alpha-1 antitrypsin deficiency**

Adult patients affected by alpha-1 antitrypsin deficiency are usually asymptomatic. Only a small portion of this population shows abnormal liver enzyme levels (25,26). A study based on autopsies performed on affected individuals
showed that 50% of cases had cirrhosis, which evolve to hepatocarcinoma (HCC) in 28% of cases (27).

When alpha-1 antitrypsin deficiency is suspected, a genetic test can be helpful when combined with a measurement of the plasma level of alfa-1 antitrypsin (28). In case of end-stage liver failure, LT is the only effective treatment (29), with an excellent 5-year OS and graft survival of 83% and 77% being respectively achieved (30).

Hereditary hemochromatosis (HH)

HH is a metabolic disease related to an excess of hepatic iron. In 4–6% of patients, it is related to the mutation of C282Y and can lead to liver cirrhosis (30). Therapeutic phlebotomy can help to decelerate the disease, but end-stage liver disease (31) is often inevitable (32,33). Furthermore, studies have shown that HH increases the risk of HCC development, which occurs predominantly in patients with cirrhosis at the time of diagnosis (34). A high level of iron could be seen in patients with other causes of liver disease, and a combination with HH is quite rare (34).

This disease represents 0.5–1% of all LT indications (35), and a small portion of all patients progress to LT. Since the excess of iron in the heart can lead to congestive heart failure, a strictly cardiovascular work-up before LT is mandatory (36).

Polycystic liver disease (PLD)

The PLD consists of multiple simple cysts in the liver more than 1 cm in size, with no sign of infection or traumatic origin (37).

PLD can be associated with autosomal dominant polycystic kidney disease (ADPKD, caused by mutations in the PKD1 gene and PKD2 gene) or can be an autosomal dominant PLD (ADPLD, caused by mutations in the PRKCH gene among others).

PLD is most frequently associated with ADPKD, while ADPLD is less common and occurs in the absence of renal cystic involvement. In patients with ADPKD, the kidney cysts usually precede the liver cysts. This disease is prevalent in females, because the hepatic cystogenesis is sex-dependent, at least in the fertile age (38,39).

Pathogenesis seems to be related, at least in most of cases, to ductal plate malformation associated with ciliary defects, and cholangiopathy results from abnormalities in the late stages of embryonic liver development. This disease leads to a progressive growth of fluid cysts that gradually may replace liver tissue. With aging, the number of cysts and total liver volume increase, and an annual growth rate of 0.0–3.2% has been estimated (37-39).

Renal involvement or hepatomegaly are primarily responsible for the following symptoms related to abdominal compression: abdominal pain, abdominal distention, dyspnea, dyspepsia, and complications secondary to portal hypertension or bile duct compression. On rare occasions, PLD can lead to acute symptoms due to cyst hemorrhage, rupture, or infection, but liver failure and death from isolated PLD is extremely unlikely (40). However, due to the slow cyst growth, the vast majority of patients with PLD are asymptomatic. Possible manifestations usually do not appear before 50 to 60 years of age. Female gender, advancing age, and large renal cysts are risk factors for liver cyst growth (37,39).

Few medical treatments are currently available for PLD, but somatostatin analogues like octreotide and mTOR inhibitors have been used with variable success, with an effect that seems more pronounced on renal involvement (37,40). Sclerotherapy, laparoscopic fenestration, and liver resection are usually offered in cases of symptomatic PLD. However, when symptoms are not manageable (abdominal pain, abdominal distension, high risks of cyst complication, low quality of life, malnutrition due to early satiety from gastric compression by enlarged cysts) and/or not responsive to medical and surgical therapy, LT is often the only available option. Of note, in these patients, hepatic function is usually normal and the MELD score system is not informative. Exceptions have to be made for the patient to have an opportunity for transplant and to progress in the waiting list. However, even with exceptions, in UNOS area patients with PLD have a higher risk of mortality or drop out more often than listed patients with HCC (41).

Notwithstanding, data show that patients with progressive PLD might benefit from LT, with a 1- and 5-year survival of 93% and 91%, respectively. When a kidney transplant was needed, simultaneous liver-kidney transplant showed a 1- and 5-year survival of 86% and 80%, respectively. PLD represents 1% of all indications to LT (40,41).

It is interesting to note that patients transplanted for PLD have a 30-day morbidity of 41% and a mortality of 5% (39,40). These data can be attributed to intraoperative technical issues particularly during the hepatectomy phase: an average cirrhotic transplanted liver is usually 1.1 kg, while polycystic livers usually weigh 6.6 kg, with cases of 14 and 19 kg being reported (42,43). Studies also suggest that patients transplanted for PLD have higher rates of vascular
complications, with hepatic artery thrombosis in particular, which is related to a procoagulant state (40).

Considering that even untreated PLD is not associated with high mortality, the risks of surgery have to be carefully evaluated. In this setting, multidisciplinary evaluation of the patient is mandatory (37).

**LT in bariatric surgery**

Bariatric surgery may rarely lead to liver failure, especially after jejuno-ileal bypass and biliopancreatic diversion. Protein malnutrition and bacterial overgrowth are the main causes of liver damage following bariatric surgery (44). A recent systematic review analyzed 14 studies reporting 36 patients listed to LT after bariatric surgery. This group comprised cases of jejuno-ileal bypass (n=16), biliopancreatic diversion according to Scopinaro (n=14), duodenal switch (n=3), biliointestinal bypass (n=1), long-limb Roux-en-Y gastric bypass (n=1), and single-anastomosis omega gastric bypass (n=1). Liver failure developed usually within a median of 20 months after surgery, with biliopancreatic diversion being an exception where liver failure appeared with a shorter interval. Data showed that LT might be a viable option in this cohort of patients (45).

**Alagille syndrome**

Alagille syndrome is an inherited autosomal dominant multisystemic disease caused by mutation in JAG1 localized in the chromosome 20p12 (46), characterized by paucity of interlobular bile ducts at the hepatic level.

The largest parts of patients (almost 85%) are diagnosed before 6 months of age because of jaundice and failure to thrive, or cardiovascular symptoms. Other typical features are chronic cholestasis (90%), cardiac anomalies, peripheral pulmonic stenosis (85–91%), butterfly vertebrae (39–87%), posterior embryotoxon (prominent Schwalbe line) of the eye (61–88%), and dysmorphic facies consisting of broad nasal bridge, triangular faces, and deep set eyes (77–95%) (47–50). In these patients, growth and mental retardation, developmental delay, renal disease, and pancreatic insufficiency can be also present, but to a lesser extent.

Severe liver disease is indeed a major cause of morbidity. Increase in serum levels of bilirubin is the major criterion to perform biliary diversion procedures, and LT can occasionally be considered in patients with intractable pruritus, osteodystrophy, progressive liver synthetic dysfunction, or rarely, variceal bleeding. The consistency of LT for Alagille syndrome has been shown in a study of 163 patients (51), but ursodeoxycholic acid in a few cases was also demonstrated to be of some help (52).

**Neoplastic diseases with possible indication to LT**

**Benign liver tumor**

Benign liver tumors are not rare finding in the general population, but they may constitute a rare indication to LT. The three most common types of benign liver tumors are hepatic hemangiomas (HHes), focal nodular hyperplasia (FNH), and hepatocellular adenomas; they rarely require medical or surgical treatment (53). Hepatic hemangioma is the most frequent benign liver tumor. It consists of multiple, large, distorted blood vessels with a single layer of endothelial cell filled with blood and nourished by the hepatic arterial circulation. Usually HHes manifest as single lesions, but multiple liver lesions also occur (54).

HHes incidence in the general population ranges from 0.4% to 20%, and is most commonly diagnosed as incidental finding between the ages of 30 and 50 years old, more often in females. HHes with a diameter larger than 10 cm are defined as giant liver hemangioma (54). HHes are usually asymptomatic, but giant or cavernous HHes, as in cases of PLD, can cause compressive symptoms related to the massive hepatomegaly. Acute complications of HHes are rare, but can be life threatening. A spontaneous or traumatic rupture of a giant HHes is uncommon (1–4%), but the mortality is elevated (36–39%); Kasabach-Merritt syndrome (KMS) (giant liver HHes, associated with thrombocytopenia, intravascular coagulation, consumptive coagulopathy) can progress to disseminated intravascular coagulation and multi-organ failure (MOF) (55). In this scenario, treatment and surgery is usually indicated, even if there is no consensus regarding the optimal management: liver resection, enucleation, irradiation, or selective embolization of the feeding hepatic artery. Although LT is rarely performed, it has to be considered in order to prevent HHes complications (55–57). A recent review, reporting 19 cases of LT for giant HHes, suggested LT for non-resectable HHes in patients with imminent life-threatening complications (especially KMS), an increased risk of malignant transformation, an underlying liver disease, or the presence of severe symptoms (58). FNH and hepatocellular adenomas are not an indication for LT by themselves, but they are if associated with another liver disease, which was the indication for LT (59,60).
CCA

CCA is a malignant tumor with features of biliary differentiation. It is rare in the Western world, occurring in 0.5–2 individuals per 100,000 per year, but the disease has a much higher incidence in the Asian population. Despite this, CCA is the second most common primary liver cancer after HCC, and the incidence of the disease is especially high in patients with PSC (61).

CCA can be classified according to its locations on the biliary tree, and requires different diagnostic and treatment approaches: intrahepatic (iCCA), distal (dCCA), and perihilar (pCCA) cholangiocarcinoma. iCCA and dCCA, as a result of poor results related to LT, are still contraindications to LT, while pCCA is a potential indication to LT (62). In pCCA, surgical resection with a negative margin (R0) is the most favorable prognostic factor, but unfortunately, it is only possible in 25–40% of the patients and has a 5-year survival rate of 40% (63,64).

Given this setting, LT could offer better survival in patients with an unresectable pCCA at risk of R1/R2 or of post-hepatectomy liver failure due to inadequate future liver remnant (65,66). The first LT experience for pCCA presented poor results, with a 3- and 5-year survival ranging from 30% to 23% respectively, with a high rate of recurrence (67-69). In 1993, a Mayo Clinic protocol for pCCA was introduced, consisting of external beam radiation therapy (45 Gy in 30 fractions, 1.5 Gy twice daily), brachytherapy (20 Gy at 1 cm for approximately 20–25 hours), and capecitabine until the time of LT. Before LT, laparoscopic abdominal staging is necessary in order to exclude metastatic disease and to assess lymph nodes status (66). The first positive results, showing an OS after LT at 5 years of 74%, were reported in multicentric studies (70). This advantage in term of OS was also confirmed for unresectable hilar CCA and hilar CCA arising in the setting of PSC. PSC is a rare disease (prevalence less than 50 per 100,000) and it is a well established indication to LT in patients with intractable pruritus, recurrent bacterial cholangitis, or poor liver function. Ten-twenty percent of patients with PSC develop CCA, and in this setting LT has been shown to provide an important therapeutic tool (66).

Although the Mayo Clinic protocol represented indeed a breakthrough, some aspects are hitherto under debate. Data are still insufficient to determine whether the results may be biased by the high selection of the patients due to the strict protocol, or by the efficacy of the pre-LT therapy itself. Furthermore, considering that mass biopsy prior to LT is at high risk of seeding, one series reported a 15% liver with no sign of cancer after LT, suggesting that the initial diagnosis of pCCA was not correct (71). However, LT showed a better 5-year survival compared to patients who received liver resection (18% vs. 64%) (72). How to prioritize LT for pCCA is still matter of controversy. Recently, hilar CCA arising in the setting of PSC has been established to be correlated with good outcome after LT, and MELD score exception has been proposed to prioritize the patients in the waiting list (73).

Epithelioid hemangioendothelioma (EHE)

EHE is a rare vascular tumor originating from vascular endothelial and mesenchymal epithelioid cells. It is associated with a low-intermediate grade of malignity, between benign hemangioma and malignant angiosarcoma, with a low risk of metastatic disease (74).

Primary malign EHE is a very rare tumor (incidence less than 1/1 million), predominantly presenting in women (61% of cases) between 30 and 40 years of age (75).

Most of the patients are asymptomatic, and the diagnosis is accidental. Symptoms are related to the growing of the tumor mass, mostly consisted of stroma. Abdominal pain, portal hypertension, symptoms secondary to abdominal mass, and liver failure can be present. Laboratory studies and imaging studies can suggest the diagnosis of EHE, but the final diagnosis is made histologically with immunohistochemistry (76).

In EHE, disease history has exhibited a 4.5% (75) patient survival rate, but systemic chemotherapy has shown no OS benefit. Liver resection and other therapeutic options such as ablative techniques, transarterial chemoembolization (TACE), and radiation therapy are frequently the first treatment choice and have yielded excellent results (5-year OS of 75%), but they are often not feasible due to the multinodular and bilobar presentation of the disease. In this setting, LT seems to be the most favorable choice of treatment, even if extrahepatic disease is present, and has achieved a low rate of recurrence and a 5-year OS following LT ranging from 54% to 83% (77).

Studies performed by the European Liver and Intestine Transplant Association (ELITA) and ELTR were the first based on a large cohort and long follow-up, and proved that LT is a viable treatment option. These studies examined a total of 149 patients transplanted for EHE, reporting a 10-year disease-free survival (DFS) of 73% with an 10-year OS
of 77% (78-80). Meanwhile, the UNOS registry reported a 5-year survival rate of 64% in 110 patients transplanted for EHE (80). Based on these studies, it is difficult to estimate the risk of progression from EHE to hemangiosarcoma after LT. However, data showed that patients transplanted for hemangiosarcoma showed a lower overall survival (less than 2 years) than patients transplanted for EHE (78-80).

Recently, the therapeutic algorithm for EHE based on risk of recurrence and extrahepatic disease localization was proposed, allowing for a better management of the disease (78,81).

**Neuroendocrine tumors (NETs)**

NETs are rare tumors, with an annual incidence of 5 cases per 100,000 people (82). They are produced by cells of the neuroendocrine system found throughout the digestive tract, and their biological behavior can be heterogenous. Usually this disease is diagnosed when already metastasized, predominantly to the liver (46–93%) (83). Intestinal and pancreatic NETs are the most common source of liver metastasis. NETs are slow-growing tumors, but the involvement of the liver heavily impinges on the OS. For instance, a 13–54% rate of 5-year OS in the presence of liver metastases was reported compared to the OS of 75–99% in non-metastatic NETs (84). Liver resection proved not to be very effective for improving the OS, making LT in highly selected patients with unresectable liver metastasis NETs as the only potential curative treatment. The presence of extrahepatic disease (previous peritoneal carcinomatosis and distant lymph nodes) is an absolute contraindication to LT; in this scenario, a staging laparoscopy might be helpful before LT.

LT for liver metastatic NETs is usually indicated in the case of unresectable liver metastases not approachable by other medical or surgical treatments (so-called oncological indication) or unresectable liver metastases with refractory symptoms (hormonal and tumor bulk indications).

Studies have reported a 5-year OS of 47–97% and disease-free survival rates of 32–87% after LT. A recent review reported an overall post-LT recurrence ranging from 31.3% to 56.8%, with a 1-, 3-, and 5-year OS of 89%, 69%, and 63%, respectively (85). More than 50% of liver involvement, high Ki-67 index, and pancreatic primary localization were associated with worse long-term survival after LT (86). However, lacking long-term results and prospective trials, LT for liver metastatic NETs is still highly controversial. Milan-NET criteria (86,87), UNOS guidelines, or the European Neuroendocrine Tumor Society (ENETS) guidelines (88) have tried to standardize the indication to LT, but patient selection criteria are still poorly defined (Table 4) (89), and whether stable disease or progressive disease is an indication to LT is still a matter of debate.

**Colo-rectal liver metastases**

Colorectal cancer (CRC) is the third most common tumor worldwide and liver metastases develop in 20–30% of cases, strongly affecting the long-term outcome of patients (90). The current gold standard treatment for colorectal liver metastasis (CRLMs) is represented by local treatment based on liver resection, and is associated with systemic chemotherapy, yielding a 5-year survival of 31–58%. However, liver resection is feasible in only 20% of the patients, and palliative chemotherapy is associated with poor outcome (5-year OS of 10%) (91). In this setting, recent studies and trials are showing that, in highly select patients, LT for unresectable CRLM is a viable option with good long-term outcomes. The SECA-II study, a randomized controlled clinical trial of 15 patients transplanted for CRLM selected according to strict criteria, showed an OS at 1, 3, and 5 years of 100%, 83%, and 83%, respectively, with a median follow-up of 36 months (92). The best option between transplantation and other treatments (chemotherapy) will depend on the results of other ongoing trials including the TRANSMET and SECA-III trials, along with the Partial Liver Segment 2/3 Transplantation Study (Table 5).

**Conclusions**

LT is the standard treatment for patients affected by liver failure that mostly results from liver cirrhosis. However, in the last few years, LT for rare diseases has been receiving considerable interest. It represents less than 1% of all indications to LT, including non-hepatocellular malignancies, vascular disorders, and metabolic and congenital liver disorders. Knowing the nonstandard indications for LT and providing an early referral to a transplant center could improve the overall survival and the quality of life in these patients.

On the other hand, rare indications to LT from non-rare diseases, including those of CRLM or cholangiocarcinoma, could have the potential to become future common indications due to the crisis of the conventional indications to LT (such as HCV-related cirrhosis), the expanded criteria for marginal donors, or an increased use of living donor LT.
Table 4 LT in patients with metastatic NETs: Milan, UNOS, and ENETS Criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Milan Criteria</th>
<th>UNOS Criteria</th>
<th>ENETS Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histology</td>
<td>Confirmed histology of low-grade NET with or without the presence of the syndrome</td>
<td>Confirmed histology of low-grade NET</td>
<td>Confirmed histology of low-grade NET</td>
</tr>
<tr>
<td>Primary tumor site</td>
<td>Primary tumor drained by the portal system already removed with a curative resection</td>
<td>Primary tumor drained by the portal system</td>
<td>N/A</td>
</tr>
<tr>
<td>Metastatic involvement</td>
<td>Metastatic diffusion to &lt;50% of the total liver volume</td>
<td>Metastatic diffusion to &lt;50% of the total liver volume</td>
<td>N/A</td>
</tr>
<tr>
<td>Disease stability</td>
<td>Stable disease/response to therapies for at least 6 months prior to transplant consideration</td>
<td>any evidence of recurrence of at least 6 months</td>
<td>N/A</td>
</tr>
<tr>
<td>Age</td>
<td>&lt;60 (relative criteria)</td>
<td>&lt;60</td>
<td>N/A</td>
</tr>
<tr>
<td>Others</td>
<td>–</td>
<td>–</td>
<td>Exclusion of extrahepatic disease</td>
</tr>
</tbody>
</table>

Table 5 Comparison between studies on LT for CRLM

<table>
<thead>
<tr>
<th>Variable</th>
<th>SECA II study (92)</th>
<th>Compagnons Hépato-Biliaires (93)</th>
<th>Toronto (NCT02864485)</th>
<th>TRANSMET</th>
<th>Oslo (NCT02215889)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of study</td>
<td>Prospective study</td>
<td>Retrospective cohort study</td>
<td>Prospective cohort</td>
<td>Prospective RCT</td>
<td>Prospective</td>
</tr>
<tr>
<td>Number of participants</td>
<td>15</td>
<td>12</td>
<td>Ongoing</td>
<td>Ongoing</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Methods</td>
<td>Whole liver from deceased donor</td>
<td>Whole liver from deceased/dominor donor</td>
<td>Living donor LT</td>
<td>Whole liver from deceased donor</td>
<td>Living donor segment 2/3</td>
</tr>
<tr>
<td>Nonresectable liver-only</td>
<td>Prevalent synchronous metastases</td>
<td>Nonresectable liver-only</td>
<td>Nonresectable liver-only</td>
<td>Nonresectable liver-only</td>
<td>Nonresectable liver-only</td>
</tr>
<tr>
<td>Response to chemotherapy</td>
<td>Response to chemotherapy</td>
<td>Response to chemotherapy</td>
<td>Response to chemotherapy</td>
<td>–</td>
<td>Stage 1: S2–S3 removed and liver donor implanted; Stage 2: After growth of donor segments, the remaining liver segments of the recipient were removed</td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>Histologically verified adenocarcinoma in the colon or rectum</td>
<td>–</td>
<td>Primary CRC with tumor stage ≤ T4a</td>
<td>Histologically verified adenocarcinoma in the colon or rectum</td>
<td>Histologically verified adenocarcinoma in the colon or rectum</td>
</tr>
<tr>
<td></td>
<td>No signs of extrahepatic metastatic disease or local recurrence</td>
<td>–</td>
<td>No signs of extrahepatic metastatic disease or local recurrence</td>
<td>No signs of extrahepatic metastatic disease or local recurrence</td>
<td>No signs of extrahepatic metastatic disease or local recurrence except in 1–3 resectable lung lesions; all &lt;15 mm</td>
</tr>
<tr>
<td></td>
<td>ECOG 0 or 1</td>
<td>–</td>
<td>ECOG 0 or 1</td>
<td>ECOG 0 or 1</td>
<td>ECOG 0 or 1</td>
</tr>
</tbody>
</table>
Table 5 (continued)

<table>
<thead>
<tr>
<th>Variable</th>
<th>SECA II study (92)</th>
<th>Compagnons Hépato-Biliaires (93)</th>
<th>Toronto (NCT02864485)</th>
<th>TRANSMET</th>
<th>Oslo (NCT02215889)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resected primary tumor with adequate resection margins</td>
<td>–</td>
<td>CT for &gt;3 months</td>
<td>Resected primary tumor with adequate resection margins</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Received first-line treatment</td>
<td>–</td>
<td>Time from primary CRC resection to transplant &gt;6 months</td>
<td>Eligible for both treatment groups</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Time criteria: 1 year from diagnosis to listing for LT</td>
<td>–</td>
<td>Stable or decreasing CEA values</td>
<td>CEA &lt;80 mg/L or a decrease &gt;50% of the highest value</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Median FU</td>
<td>36 months</td>
<td>26 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-year OS</td>
<td>100%</td>
<td>83%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-year OS</td>
<td>83%</td>
<td>62%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-year OS</td>
<td>83%</td>
<td>50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-year DSF</td>
<td>53%</td>
<td>56%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-year DSF</td>
<td>44%</td>
<td>38%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-year DSF</td>
<td>35%</td>
<td>38%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrence</td>
<td>&gt; Pulmonary</td>
<td>&gt; Pulmonary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N/A, not applicable.

for such indications.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Provenance and Peer Review:** This article was commissioned by the Guest Editors (Luca Fabris and Mario Strazzabosco) for the series “Recent Advances in Rare Liver Diseases” published in Translational Gastroenterology and Hepatology. The article was sent for external peer review organized by the Guest Editors and the editorial office.

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tgh-19-282). The series “Recent Advances in Rare Liver Diseases” was commissioned by the editorial office without any funding or sponsorship. Alessandro Vitale serves as an unpaid editorial board member of Translational Gastroenterology and Hepatology from Jan 2020 to Dec 2021. The authors have no other conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons
References


doi: 10.21037/tgh-19-282